During the last session, Allogene Therapeutics Inc. (NASDAQ:ALLO)’s traded shares were 1.97 million, with the beta value of the company hitting 0.75. At the end of the trading day, the stock’s price was $5.47, reflecting an intraday loss of -3.87% or -$0.22. The 52-week high for the ALLO share is $17.49, that puts it down -219.74 from that peak though still a striking 19.2% gain since the share price plummeted to a 52-week low of $4.42. The company’s market capitalization is $797.74M, and the average intraday trading volume over the past 10 days was 1.71 million shares, and the average trade volume was 2.06 million shares over the past three months.
Allogene Therapeutics Inc. (ALLO) received a consensus recommendation of an Overweight from analysts. That translates to a mean rating of 1.90. ALLO has a Sell rating from 0 analyst(s) out of 19 analysts who have looked at this stock. 3 analyst(s) recommend to Hold the stock while 1 suggest Overweight, and 14 recommend a Buy rating for it. 1 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.59.
25-cent Stock Takes $11T Commodities Sector Digital
One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.
All the details are in the FREE online report you can get here.
Sponsored
Allogene Therapeutics Inc. (NASDAQ:ALLO) trade information
Allogene Therapeutics Inc. (ALLO) registered a -3.87% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -3.87% in intraday trading to $5.47 this Thursday, 05/25/23, hitting a weekly high. The stock’s 5-day price performance is -10.03%, and it has moved by 0.74% in 30 days. Based on these gigs, the overall price performance for the year is -25.48%. The short interest in Allogene Therapeutics Inc. (NASDAQ:ALLO) is 40.65 million shares and it means that shorts have 21.54 day(s) to cover.
The consensus price target of analysts on Wall Street is $16.91, which implies an increase of 67.65% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $6.00 and $35.00 respectively. As a result, ALLO is trading at a discount of -539.85% off the target high and -9.69% off the low.
Allogene Therapeutics Inc. (ALLO) estimates and forecasts
Statistics show that Allogene Therapeutics Inc. has underperformed its competitors in share price, compared to the industry in which it operates. Allogene Therapeutics Inc. (ALLO) shares have gone down -48.88% during the last six months, with a year-to-date growth rate less than the industry average at 0.43% against 11.40. Yet analysts are ramping up their growth forecast for the fiscal year 2023. Revenue is predicted to shrink -13.50% this quarter and then jump 3.40% in the quarter after that. In the rating firms’ projections, revenue will decrease -71.20% compared to the previous financial year.
Revenue for the current quarter is expected to be $20k as predicted by 18 analyst(s). Meanwhile, a consensus of 18 analyst(s) estimates revenue growth to $10k by the end of Sep 2023. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled $86k and $10k respectively.
While earnings are projected to return -22.80% in 2023, the next five years will return 1.00% per annum.
ALLO Dividends
Allogene Therapeutics Inc. is due to release its next quarterly earnings between August 07 and August 11. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Allogene Therapeutics Inc. (NASDAQ:ALLO)’s Major holders
Allogene Therapeutics Inc. insiders own 29.16% of total outstanding shares while institutional holders control 78.32%, with the float percentage being 110.56%. TPG GP A, LLC is the largest shareholder of the company, while 259 institutions own stock in it. As of Mar 30, 2023, the company held over 18.72 million shares (or 12.83% of all shares), a total value of $102.38 million in shares.
The next largest institutional holding, with 9.12 million shares, is of Blackrock Inc.’s that is approximately 6.26% of outstanding shares. At the market price on Mar 30, 2023, these shares were valued at $49.9 million.
Also, the Mutual Funds coming in first place with the largest holdings of Allogene Therapeutics Inc. (ALLO) shares are SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and Smallcap World Fund. Data provided on Feb 27, 2023 indicates that SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF owns about 6.42 million shares. This amounts to just over 4.40 percent of the company’s overall shares, with a $35.12 million market value. The same data shows that the other fund manager holds slightly less at 5.31 million, or about 3.64% of the stock, which is worth about $29.05 million.
